BPC-157, TB-500 and GHK-Cu: Three Distinct Research Compounds, Not One Blended Material

BPC-157, TB-500 and GHK-Cu are frequently sold as one bundled item. That bundling is a purchasing convenience, not a scientific classification. The three materials have different sequences, different chemistries and different bodies of laboratory literature, and a laboratory that treats them as interchangeable will mis-specify at least one of them. This article separates the three compounds so that UK research and procurement teams can identify, specify and document each material on its own terms.

Why the three are grouped, and why that matters for sourcing

A multi-compound listing usually exists because a supplier expects the pair or trio to be ordered together. The grouping says nothing about how the compounds behave. It also hides the detail a laboratory actually needs: the mass of each component, the presentation, and the documentation that travels with the material.

When the three arrive as one pre-combined preparation, a research question that only concerns one of them cannot be answered cleanly, because the other two are present in the same vial. ADINA supplies BPC-157, TB-500 and GHK-Cu as separate, individually identified materials, which keeps each control arm independent and each specification attributable to a single compound.

BPC-157: a sequence studied in repair-signalling models

BPC-157 is a synthetic pentadecapeptide. In the research literature it appears in cellular and tissue-model studies of repair signalling, and it is most often described in relation to local tissue and gastrointestinal model systems. What the literature supports is a defined sequence studied under controlled conditions; what it does not support is any statement of established effect in humans or animals.

For procurement, BPC-157 is a single, well-defined peptide with a fixed amino-acid sequence, so identity is straightforward to specify and to check against a documented batch.

TB-500: a fragment, not the parent protein

TB-500 is a synthetic peptide derived from the actin-binding region of thymosin beta-4. The distinction between a fragment and its parent protein is the point that most often goes missing. A fragment is shorter, it carries a subset of the parent’s sequence, and the research questions asked of it are narrower.

TB-500 appears in laboratory work on actin organisation, cell movement and cytoskeletal behaviour. It is a different molecule from BPC-157, not a second name for it, and the two should not be ordered or documented as a single line item.

GHK-Cu: a copper-bound tripeptide, materially different from the other two

GHK-Cu is the outlier of the three, and the one that is most often mis-specified. It is a tripeptide – glycyl-L-histidyl-L-lysine – bound to a copper(II) ion. That copper centre is not a detail: it changes the material’s mass, its colour and the kind of assay it belongs in.

Because GHK-Cu is a metal-peptide complex, specification has to cover both the peptide and the bound metal. A certificate that names the peptide but does not address the copper content does not fully identify the material. Research on GHK-Cu is typically framed around copper-dependent signalling and extracellular-matrix models, and the copper is central to that framing rather than incidental.

Where the three overlap and where they diverge

The overlap is procedural, not mechanistic: all three are laboratory materials, all three are documented by lot, and all three need a defined specification before an order is raised. The divergence is in what has to be specified.

What to verify per material

Identity. Each compound needs its own name, sequence or structure, and – for GHK-Cu – its bound metal. A total mass for a combined vial does not identify any single component.

Specification. Note the presentation, the container, and the storage conditions the supplier states for that material. These are properties of the material, not marketing lines, and they belong on the internal record.

Documentation. Ask what the batch documentation actually contains and what it does not. A certificate that names the batch and the analytical method used is more useful than a generic purity statement, because it ties a number to a specific lot. Where a document is not yet available, the honest position is that it is pending, and it should be chased rather than assumed.

Research on a compound is not the same as the status of the material

One distinction governs the tone of this entire guide. A published paper describing research on BPC-157, TB-500 or GHK-Cu is evidence about a compound in a study. It is not evidence about any specific vial in a supplier’s inventory. The literature and the material are separate objects, and conflating them is the most common way a specification brief goes wrong.

That is why this article describes what each compound is and what the research looks at, and stops there. It makes no claim about human or veterinary use, no dosing guidance, and no statement of benefit. Those are outside the scope of a research material, and outside the scope of what ADINA supplies.

A short procurement brief

Before raising an order for any of the three, confirm: the exact compound and its identity data; the mass and presentation for that material separately; the storage conditions stated by the supplier; and the documentation status of the batch, including anything still pending. Request the certificate rather than relying on a listing that groups the compounds together.

ADINA lists BPC-157, TB-500 and GHK-Cu as individual materials with their own product pages, so each can be specified and documented on its own. Reviewing them separately is the difference between a research order and a bundle.